Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35608481.
- Also identified by DOI 10.1158/1078-0432.CCR-22-1137.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari et al., p. 3318.
Medical subject headings
- Brain Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms